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Abstract
Previous studies have suggested that administration of oxytocin (OT) can have modulatory effects on social and anxiety-like
behavior in mammals that may endure beyond the time of acute OT administration. The current study examined whether
repeated administration of OT to male Wistar rats (n=48) during a key developmental epoch (early adolescence) altered
their physiology and behavior in later-life. Group housed rats were given intraperitoneal injections of either 1 mg/kg OT or
vehicle during early adolescence (post natal-days [PND] 33–42). OT treatment caused a transient inhibition of body weight
gain that recovered quickly after the cessation of treatment. At PND 50, the rats pre-treated with OT displayed less anxiety-
like behavior on the emergence test, while at PND 55 they showed greater levels of social interaction. A subgroup of OT pre-
treated rats examined at PND 63 showed a strong trend towards increased plasma OT levels, and also displayed significantly
increased OT receptor mRNA in the hypothalamus. Rats pre-treated with OT and their controls showed similar induction of
beer intake in daily 70 min test sessions (PND 63 onwards) in which the alcohol concentration of beer was gradually
increased across days from 0.44% to 4.44%. However, when given ad libitum access to beer in their home cages from PND
72 onwards (early adulthood), consumption of beer but not water was significantly less in the OT pre-treated rats. A
‘‘booster’’ shot of OT (1 mg/kg) given after 25 days of ad libitum access to beer had a strong acute inhibitory effect on beer
intake without affecting water intake. Overall these results suggest that exogenous OT administered during adolescence
can have subtle yet enduring effects on anxiety, sociability and the motivation to consume alcohol. Such effects may reflect
the inherent neuroplasticity of brain OT systems and a feed-forward effect whereby exogenous OT upregulates endogenous
OT systems.
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Introduction
The neuropeptide oxytocin (OT) regulates a number of critical
behavioral repertoires in mammals including maternal behaviour
[1–3], social interaction and social preference [4,5], sexual
behaviour [6], and anxiety-like behaviour [2]. The anxiolytic
properties of OT, and related OT receptor agonists, have been
documented in many different rodent models of anxiety and with
many different routes of administration [7–11]. OT can also
reverse some of the anxiogenic effects of social separation. For
example, social interaction deficits in prenatally stressed rat pups
were reversed by administering OT into the central amygdala
[12]. Central administration of OT also reduced distress ultrasonic
vocalisation production in rat pups during social isolation, perhaps
by mimicking the effects of social contact [13]. In a more recent
study, socially isolated voles given OT peripherally showed fewer
lasting adverse effects of long-term social isolation than controls
[14]. Furthermore, chronic central OT administration in male rats
increased the duration and frequency of non-sexual physical
contact with female rats, irrespective of their oestrous cycle, which
suggests chronic OT may facilitate nonsexual social interactions
[15]. The anxiolytic and prosocial effects of OT evident in these
animal models have led to worldwide interest in exogenous OT as
a potential therapeutic for human psychiatric disorders [2,16–23].
In some published studies these effects of OT are more apparent
with repeated, rather than acute, administration. Thus chronic,
but not acute, centrally administered OT attenuated the
pathological high anxiety of female rats selectively bred for high
anxiety-related behaviour [24] while 3 days of peripheral OT
treatment significantly reduced anxiety in rats following the
induction of colitis [25]. In other studies, repeated peripheral OT
treatment had lasting beneficial effects on blood pressure and pain
tolerance [26,27] and causes long-lasting decreases in blood
concentrations of corticosterone [10,28]. Even more striking, rats
administered 1 mg/kg OT peripherally once per day from
postnatal days 1–14 showed significantly reduced blood pressure
in adulthood (aged 7–8 months) [29].
The ability of exogenous OT to cause enduring residual
changes in behavioral and physiological traits may reflect the
inherent plasticity of OT neural systems. Heightened stimulation
of hypothalamic OT receptors (OTRs) triggers increased dendritic
and peripheral release of OT which further stimulates OTRs
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the oxytocinergic neurons, decreased astrocytic coverage of
neurons, and a subsequent increase in juxtaposition of neurons
at the level of somas and dendrites across the entire OT system (for
a review see [30]). Ultimately, this process results in a lasting
increase in the productivity and functionality of the OT system,
the duration of which can last for months depending on the
magnitude and length of the stimulation [31–33]. Importantly
from a therapeutic perspective, these changes can be induced both
in vivo and in vitro by administration of exogenous OT [34–37]. Of
particular relevance to the present study, plasticity has been
demonstrated in the hypothalamic magnocellular neurons of
adolescent male rats [38] and robust changes in OTR density
occurs in a number of brain regions during adolescent develop-
ment [39].
Adolescence is a key developmental epoch in mammals during
which sexual maturity is attained and adult behavioral repertoires
rehearsed and consolidated. Many human psychiatric problems
have their ontogeny in perturbations in adolescent development
caused by trauma or drug and alcohol abuse [40,41]. Accordingly,
the present study sought to characterize the potential of OT
administration, when given chronically during adolescence, to
modulate social behavior, anxiety, and alcohol consumption.
Alcohol was of interest given the ample evidence that both
centrally and peripherally administered OT can reduce tolerance,
dependence and self-administration of various drugs of abuse
through interaction with neural sites implicated in the develop-
ment of drug addiction and craving [18,42–46]. Several studies
report lower tolerance to and consumption of alcohol amongst
breastfeeding mothers (in whom the central OT system is
upregulated) compared to non-lactating mothers [47–49]. OT
administered both centrally and peripherally during chronic
ethanol treatment attenuates the development of tolerance to
ethanol-induced hypothermic, myorelaxant and akinesic effects in
mice [50,51], and decreases the severity of withdrawal symptoms
in mice [52]. In rats, peripheral OT attenuated tolerance to
alcohol-induced narcosis [53].
We therefore predicted that rats given repeated OT treatment
during adolescence might exhibit altered alcohol self-administra-
tion in adulthood. To test this hypothesis we utilized the beer
model, a well-established and ecologically valid model of alcohol
consumption [54–57], which has been successfully used to test a
number of pharmacotherapies for alcohol consumption and
alcohol-related disorders [58–60]. Given that OT inhibits the
development of ethanol tolerance (see above), and inhibits drug-
induced activation of addiction-relevant brain regions [43], we
predicted that OT pre-exposure might affect alcohol consumption.
However, we hypothesized that differences in consumption might
only emerge towards the end of a long period of continuous
alcohol access as it can take several weeks for tolerance [61,62]
and ethanol-induced neuroadaptations to occur [63] with
voluntary consumption. We additionally predicted that OT pre-
treatment might alter anxiety and social behavior, and be
accompanied by long-term up-regulation of endogenous OT
systems.
Methods
Subjects
All experimental procedures were conducted in accordance
with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (7
th Edition, 2004) and were
approved by University of Sydney Animal Ethics Committee
(approval number L29/11-2009/3/5178). The subjects were 48
male Australian Albino Wistar (AAW) rats (Animal Resources
Centre, Perth, WA, Australia). They were brought to our facility at
PND 21 and handled extensively for 11 days prior to treatment.
All rats were housed 8 per cage with ad libitum access to food and
water. The rats were at PND 33 at the start of dosing, an age
corresponding to early adolescence. At this time they weighed
127–177 g.
Drugs
OT was obtained from Auspep Ltd (Parkville, Victoria,
Australia) and was dissolved in 0.9% saline vehicle at a
concentration of 1 mg/ml and injected intraperitoneally (IP) at a
dose of 1 mg/kg. This dose was chosen as several studies have
demonstrated long lasting changes following repeated peripheral
administration of this dose of OT [26–29].
Experimental design
An overview of the experimental protocol is presented in
Figure 1. Drug administration was conducted between PND 33–
42 as this is widely considered to correspond to the early
adolescent period in the developmental life cycle of the rat [64,65].
This period was of particular interest as adolescence is considered
a key developmental epoch in humans, during which many
psychological and addictive disorders have their roots [40,41].
The eight day washout before the start of testing was
implemented to allow the acute effects of the drug to completely
dissipate and to allow the subjects to reach late adolescence. Late
adolescence was of particular interest as it is the developmental
period during which many psychological disorders, such as
generalized and social anxiety become manifest in humans [40].
Furthermore, this washout period allowed the average body
weight of the two conditions to return to the same level after
transient inhibition of weight gain in the OT-treated rats. The
social interaction test was conducted five to six days after the
emergence test to minimize possible carry forward effects from one
test to the other (see Figure 1).
The brain and plasma analysis was conducted on samples taken
on PND 63 as this corresponds to early adulthood in the rat
[64,65] and it was of particular interest to see if OT pre-treatment
was capable of causing physiological and neural changes that
would endure into adulthood. Alcohol induction also began at
PND 63 as, in humans, young adulthood is the period during
which excessive patterns of alcohol consumption usually develop
[66]. Furthermore, previous research has identified this as a key
phase for the development of excessive alcohol consumption in
rats [65].
Drug administration phase
Rats were treated daily with OT 1 mg/kg (group referred to as
OT, n=24) or vehicle (group referred to as VEH, n=24) for 10
days, from PND 33–42. Body weight was recorded four times
during the drug administration phase to establish any effect of OT
on weight gain. Subjects were also weighed before the start of the
critical tests conducted in the post-drug administration phase to
ensure that average weight did not differ significantly between
conditions. Body weight was measured throughout the alcohol
administration period to ensure there were no differences in body
weight which might explain any differential consumption of
alcohol.
Post –drug behavioral testing: Emergence test
After an 8 day washout period, all rats were tested in the
emergence test. This was conducted as previously described [67]
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wooden walls and a black floor. A red Perspex hide box measuring
23 (W)622.5 (L)614.5 (H) cm, with a single opening at its center,
was placed flush against the center of one of the walls. Testing took
place under two bright white spotlights shining directly onto the
arena from opposite sides. A camera mounted to the ceiling
directly above the apparatus fed video of the tests to a computer
and monitor in an adjacent room where the sessions were scored
electronically by automatic tracking software (TRACKMATE 1.0;
MotMen Ltd, Cook Hill, NSW, Australia). The tracking accuracy
of the software has been validated over several years of use in our
laboratory with the version used for this study validated using a
large cohort of rats (n=64) and two experienced hand scorers.
The test commenced with individual rats being placed alone
inside the hide box by the experimenter. Over a 5 min period the
software automatically scored the distance travelled by each
subject during the session as well as the time spent (a) in the hide
box, (b) with head protruding outside the hide box, (c) in the open
field, and (d) in the third of the arena farthest from the hide box
(far zone). Additionally, the number of rats to emerge from the
hide box in each condition was compared across the two groups.
At the end of the 5 min the rat was returned to its home cage and
the hide box and arena were thoroughly cleaned with 70% ethanol
and allowed to dry before the next rat was tested.
Post –drug behavioral testing: social interaction test
Five to six days after the emergence test, and 13 days after the
end of drug treatment, rats were tested in the social interaction
test. The test arena measured 200 (W)6200 (L)680 (H) cm and
consisted of black walls and a black floor. Testing took place under
red light. A camera mounted to the ceiling directly above the
apparatus projected video of the tests to an external computer and
monitor where the sessions were scored electronically by
automatic social tracking software (TRACKMATE SOCIAL v.
0.9; MotMen Ltd, Cook Hill, NSW, Australia). The social tracking
capability of this software has been validated using a large cohort
of rats (n=64) and two experienced hand scorers.
Social interaction testing was conducted on a single day when
the rats were at PND 55. Each rat was matched with a rat of the
same experimental condition (OT or VEH) and body weight
(within 10 g) but from a different home cage, making a total of 12
pairs from each condition. Each pair was placed in the centre of
the arena for 5 min and the amount of social interaction and
distance between the two rats over time was automatically scored
by the software. The dependent variables of interest were the time
animals spent in close proximity to each other (within 1.5 body
lengths), the number of active social contacts over the session
(these include instances of following, head to head investigation,
anogenital investigation and adjacent lying), the average distance
travelled for each pair (travelled activity), and the average body
movement while stationary for each pair (non-travelled activity).
The arena was thoroughly cleaned with 70% ethanol and allowed
to dry before the next pair was tested.
Post –drug behavioral testing: alcohol consumption
A total of 21 days after cessation of OT or VEH pre-treatment
(PND 63), 16 rats, 8 per group, were randomly selected to test
adult consumption of beer. Rats were initially introduced to
alcohol using a lickometer system (as described in [57]) over 9 days
of testing. Briefly, this apparatus contains 16 individual chambers
that each contained two tubes through which solutions are
delivered. The rat licked the tube a certain number of times to
receive a predetermined quantity of the solution. In this case, a
0.07 ml drop of solution was provided after every 3 licks at a tube.
A step up procedure was used where the concentration of
alcohol in the beer was gradually increased over days. The base
solution used was Coopers Ultra-Light 0.44% Alcohol Beer
(‘‘near-beer’’). Ethanol was then added to the ‘‘near-beer’’ to make
1.44%, 2.44%, 3.44%, and 4.44% ethanol containing beer.
‘‘Near-beer’’ was used as an initial low-alcohol control for any
non-specific treatment effects on appetite or taste preference [58].
We have shown that even high levels of ‘‘near-beer’’ consumption
do not produce behavioral changes indicative of intoxication [56].
Both tubes in each of the 16 lickometer cages were filled with:
‘‘near-beer’’ on day 1, 1.44% beer solution on day 2, 2.44% beer
solution on day 3, 3.44% beer solution on day 4, 4.44% beer
solution on days 5–9. Daily sessions in the lickometer ran for
70 min.
Following the ninth and final lickometer session, on PND 72,
rats were placed in individual housing where they had 24 h access
Figure 1. Experimental procedures. There were 24 VEH and 24 OT subjects for inital drug administration, washout and residual testing. Eight VEH
and Eight OT subjects from the initial 48 subjects then underwent alcohol induction on PND 63–72 and were used in the subsequent experiments
conducted between PND 72–97. Another five VEH and five OT subjects taken from the initial 48 subjects were culled on PND 63 and their brain and
blood was later analysed. Abbreviations: VEH=vehicle; OT=oxytocin; PND=post natal day.
doi:10.1371/journal.pone.0027237.g001
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Water and beer bottles were weighed and changed at the same
time each day (in the middle of the dark cycle) and mls consumed
were calculated.
Following the final measurement of intakes on day 25 (PND 97),
rats in the OT group received a further 1 mg/kg ‘‘booster’’
injection of OT, while control rats received an equivalent saline
injection. Ten minutes after injection rats were placed back in
their home cage with access to 4.44% beer solution and water.
Two-and-a-half hours later the mls consumed of water and beer
were calculated so that the effects of the ‘‘booster’’ shot of OT on
beer intake could be assessed.
Blood collection and brain dissection
At PND 63, 21 days after the end of drug treatment, 10 rats (5
OT & 5 VEH), that had not been exposed to alcohol, were
decapitated using a guillotine. Immediately after decapitation,
trunk blood for each rat was collected and each brain was
dissected, and the hypothalamus was removed, snap-frozen in
liquid nitrogen then stored at 280uC as previously described [68].
Trunk blood for each rat was placed into Lithium Heparin tubes
and stored on ice before all samples were centrifuged at 10006g
for 10 min at 4uC. Blood plasma supernatant for each sample was
collected from the spun tubes and stored individually at 280uCa s
previously described [69].
RT-PCR
Each of the 10 frozen hypothalamic tissue samples was
homogenized using a rotor-stator homogenizer and RNA was
extracted using the RNeasy Mini Kit (QIAGEN, Doncaster, VIC,
Australia) according to the manufacturer’s instructions. The
quality and concentration of extracted RNA was determined
using a Nanodrop 2000 spectrophotometer (ThermoScientific,
Scoresby, VIC, Australia). Samples were stored at 220uC. RNA
was reverse transcribed to cDNA for each sample according to
protocols from Applied Biosystems (Mulgrave, VIC, Australia) in a
20 ml reaction containing: 2 mlo f5 6buffer RT; 0.33 ml of DTT;
0.33 ml RNasin; 1 ml of 10 mM dNTP mix; 1 ml of 1 mg/ml
random primers; 0.5–1 mg of template RNA (quantity dependent
on concentration of RNA); and RNase free water (quantity
dependent on concentration of RNA). Samples also contained 1 ml
of reverse transcriptase whereas negative controls contained none.
The reaction mix was incubated in a gradient thermal cycler at
37uC for 1 h then at 70uC for 15 min to inactivate reverse
transcriptase. Samples were stored at 220uC.
cDNA was prepared for amplification according to protocols
from Applied Biosystems (Mulgrave, VIC, Australia) on a 96 well
reaction plate. Each 25 ml reaction contained: 12.5 ml of Taqman
Universal PCR Master Mix, No AmpErase UNG (26); 1.25 mlo f
20618S Taqman Endogenous Control Mix; 1 ml of cDNA; 9 ml
of water. Finally, each 25 ml reaction contained 1.25 ml of the
relevant 206Taqman Gene Expression Assay Mix: rat OT gene
expression assay or rat OTR gene expression assay.
Following preparation, the plate was centrifuged at 10,000 rpm
for 30 s at 25uC. Relative quantification was then performed using
real time PCR on ABI PRISM 7000 detection system (Applied
Biosystems, Mulgrave, VIC, Australia) using thermal cycling
conditions consisting of an initial denaturation stage of 10 min at
95uC, then 40 cycles at 95uC for 15 s, annealing at 60uC for
1 min. Two negative controls were included, one containing no
cDNA template, the other containing the negative control mix
from the reverse transcription stage. Reactions for each biological
sample and the negative controls were run in triplicates. Two
plates were run in total, one for each target gene of interest: OT
and OTR.
ELISA
Determination of plasma OT concentration was performed as
using an Oxytocin Enzyme Immunoassay Kit (Assay Designs, Ann
Arbor, MI, USA) according to manufacturer instructions. The
only additional substance required was a protease inhibitor
(Sigma-Aldrich, Castle Hill, Australia), which was added to the
samples, and deionised water. All samples were run in duplicate
and standards were prepared to allow determination of concen-
tration. Prepared plates were analyzed using a microplate reader
and analysis involved comparisons of the unknown samples with a
standard curve generated from internal standards. Results were
expressed as the plasma concentration of OT in pg/ml for each
sample.
Statistics
Body weight data were analysed using mixed model ANOVA
with trend analysis of the dosing period used to establish
differences in weight gain and follow up contrasts in the post-
treatment period used to verify that the two groups returned to
and remained at the same weight after the cessation of treatment.
Data from the emergence test and social interaction tests were
analysed using independent samples t-tests. Additionally, the
number of rats to emerge from the hide box in each condition was
compared using a Chi-Square Test of independence. Pattern of
beer and water consumption over the 25 days home cage access
were examined using mixed model ANOVA and planned
contrasts were conducted to compare the intake between the
two groups on each day. Given the number of comparisons
required, a decision wise error rate (DER) was used as is
recommended by Perneger [70]. Total beer and water consumed
over the 25 days, the last week, and in the 2.5 h following the
‘‘booster’’ shot were examined using independent samples t-tests.
The analysis for the RT-PCR was conducted using ABI PRISM
7000 detection system software 7000 SDS version 1.3.1.21
(Applied Biosystems) to obtain CT values for gene expression
and statistical analysis was conducted using Relative Expression
Software Tool (REST) version 2.0.7 (Corbett Research Pty. Ltd.).
Relative gene expression was analysed for statistical significance
for each normalised target gene (OT and OTR) comparing the
OT pre-treated samples to the VEH samples.
For the ELISA the average OT plasma concentration was
compared across groups using an independent sample t-test.
Welch’s correction for unequal variances was used wherever the
assumption of homogeneity of variance was violated as indicated
by a p-value,0.05 on Levene’s test for homogeneity of variance.
Results
Body weight
At the start of dosing there was no difference in body weight
between OT (M=150.37, SD=8.90) and VEH (M=150.83,
SD=11.29) rats, p=0.877. However over the dosing period
weight increased at a significantly greater rate for VEH compared
to OT rats, as indicated by the significant linear interaction trend,
F(1,46)=7.34, p,0.01. However, despite this difference in weight
gain there was no significant difference in mean weight between
OT (M=203.77, SD=13.01) and VEH (M=211.08, SD=19.84)
rats on the last day of treatment, p=.138. There was no significant
difference in body weight between OT (M=297.79, SD=15.73)
and VEH (M=301.71, SD=21.17) rats at the start of behavioral
testing, 8 days after the cessation of dosing, p=0.471. Further-
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throughout the alcohol administration period (all p-values.0.05),
with OT (M=442.50, SD=30.90) and VEH (M=450.62,
SD=20.37) subjects equivalent in weight at the end of the
experiment when the final ‘‘booster’’ shot was given p=0.546.
Emergence test
The Chi-Square test of independence revealed significantly
more OT pre-treated rats emerged from the hide box during the
5 min session (15 out of 24) compared to VEH treated rats (4 out
of 24), x
2(48)=10.54, p=0.001. Rats pre-treated with OT spent
significantly: less time in the hide box [t(35.827)=2.30, p=0.027];
more time in the open field (Figure 2A) [t(34.256)=2.51,
p=0.017]; and more time in the far zone of the open field
(Figure 2A), t(24.995)=2.96 p,0.01. Furthermore, the OT pre-
treated rats travelled significantly more distance during the session
compared to the VEH pre-treated animals (Figure 2B),
t(28.89)=2.12, p=0.043. There was no significant difference
between OT and VEH animals in time spent with head out of the
hide box, p.0.05.
Social interaction test
OT pairs spent significantly more time than VEH pairs in close
proximity to each other (Figure 3A), t(22)=2.17, p=0.041. OT
pairs also came into social contact significantly more times than
VEH pairs (Figure 3B), t(22)=2.12, p=0.045. As seen in Figure 3C,
OT rats travelled significantly more meters than VEH animals
during the social interaction test, t(22)=2.68, p=0.014.
Consumption during alcohol induction and continuous
access to beer
During the alcohol induction period in the lickometer
apparatus, during which alcohol concentrations were gradually
increased in daily 70 min sessions, there were no significant
differences between OT and VEH pre-treated subjects in the
consumption of any ethanol concentration of beer (see Figure 4):
‘‘near-beer’’ (.44%) (p=0.794); 1.44% (p=0.556); 2.44%
(p=0.490); 3.44% (p=0.320); or 4.44% (all p-values.0.421).
Figure 5 illustrates the consumption for OT and VEH pre-
treated subjects over the course of the continuous access period for
beer and water under individual housing. There was no significant
overall pre-treatment effect on beer or water consumption, both p-
values.0.05. However, the OT pre-treated animals consumed
significantly less beer than the VEH pre-treated animals on day 2
[F(1, 14)=9.55, p,0.01], 13 [F(1, 14)=5.71, p=0.031], 20 [F(1,
14)=5.47, p=0.035], 21 [F(1, 14)=5.34, p=0.037], 23 [F(1,
14)=9.08, p,0.01] and 25 [F(1, 14)=6.84, p=0.020] of
continuous access.
Figure 2. Emergence test. Results from the 5 min emergence test conducted 8 days after the cessation of 10 consecutive days of once per day
treatments with either 1 mg/kg OT or VEH. A. Mean (+SEM) seconds spent in the open field and in the third of the open field farthest from the hide
box (far zone). B. Mean (+SEM) metres travelled during the test. N=24 per condition. * Significantly different to VEH, p,0.05 ** Significantly different
to VEH, p,0.01.
doi:10.1371/journal.pone.0027237.g002
Figure 3. Social interaction test. Results from a 5 min social interaction test conducted 13 days after the cessation of 10 consecutive days of once
per day treatments with either 1 mg/kg OT or VEH. A. Mean (+SEM) seconds the two subjects spent in close proximity (within one body length). B.
Mean (+SEM) number of active social contacts between the subjects. C. Mean (+SEM) meters travelled by each pair of subjects (on average) during
the social interaction test. N=24 per condition. * Significantly different to VEH, p,0.05.
doi:10.1371/journal.pone.0027237.g003
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pre-treated rats consumed significantly less beer in total than the
VEH pre-treated rats, t(14)=2.24, p=0.042. This emerging
difference was further reflected by VEH animals alcohol intake
showing a significant linear increase over the 25 days [F(1,
7)=7.85, p=0.026] and OT animals showing no such increase,
F(1, 7)=3.47, p=0.105. OT pre-treated animals consumed
significantly more water than VEH pre-treated animals on day
17 [F(1, 14)=7.12, p=0.018] but there were no significant
differences in water consumption on any other days, all p-
values.0.05.
Effects of an OT ‘‘booster’’ shot on beer consumption
Figure 6 illustrates consumption of beer and water in the 2.5 h
following a ‘‘booster’’ treatment with OT or VEH saline.
Following the ‘‘booster’’ dose OT subjects consumed significantly
less beer than VEH subjects, t(14)=3.13, p,0.01. There was no
significant difference in water consumption between OT and VEH
subjects, p.0.05.
RT-PCR
All samples were clean and had adequate RNA concentration
(data not shown). There was no amplification in negative controls,
indicating expression in biological samples was not due to
contamination. OTR mRNA was significantly up-regulated in
OT animals to 1.35 fold higher expression than the VEH animals
(Figure 7A), p=0.032. OT mRNA expression was essentially equal
in OT and VEH animals (fold difference=0.958), p.0.05.
ELISA
In the cohort of adolescent Wistar rats, there was a strong trend
towards significantly greater plasma OT concentration (pg/ml)
(Figure 7B) in the OT compared to VEH animals, t(8)=2.22,
p=0.057.
Discussion
The current results provide intriguing preliminary evidence that
repeated exposure to exogenous OT in adolescence can have
subtle yet significant effects that last into adulthood, effects that are
potentially significant in a clinical sense. These effects include (1)
reduced anxiety, (2) increased sociability, (3) decreased alcohol
consumption, and (4) up-regulated OT in plasma and OTR
mRNA in the hypothalamus. In addition, we demonstrated that a
‘‘booster’’ shot of OT can have an additional acute inhibitory
effect on alcohol consumption. These effects are now discussed in
turn.
Inhibited body weight gain over dosing period
Over the 10 day dosing period OT treated rats gained weight at
a significantly slower rate compared to VEH treated rats.
Previously reported effects of OT on body weight gain are
somewhat contradictory with studies reporting both increases and
reductions in weight gain after OT administration [71,72].
Reductions in weight gain or weight loss have been associated
with an acute decrease in food intake for several hours following
OT administration [72]. Increases in weight gain following OT
administration are not associated with any change in food intake
but rather with neuroendocrine changes that promote anabolic
metabolism [71]. Most likely there are strain and possibly sex and
developmental differences that dictate the effect of OT on weight
gain which may depend on factors such as endocrine profile and
sensitivity to OT. Weight quickly recovered and at the start of
behavioral testing, one week after the cessation of OT adminis-
Figure 4. ‘‘Near-beer’’ and beer consumption during the 9 day alcohol induction phase in the lickometer apparatus. Mean (6 SEM)
consumption (in mls) of increasing concentrations of beer (from .44% ‘‘near-beer’’ up to 4.44% EtOH beer). The 9 day induction period began 21 days
after the cessation of 10 consecutive days of once per day treatments with either 1 mg/kg OT or equivalent VEH saline. Subjects were placed in the
lickometer for one 70 min session per day. N=8 per condition.
doi:10.1371/journal.pone.0027237.g004
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subjects and this lack of difference remained throughout the study.
This suggests the effect of OT on weight gain is transient and
caused by the direct effects of the exogenous OT [73].
Reduced generalized anxiety
More than one week following the cessation of pre-treatment
the subjects given OT showed a marked reduction in generalized
anxiety-like behavior in the emergence test. Additionally, over 2
weeks after cessation of pre-treatment, subjects given OT had
increased sociability and activity in the social interaction test, with
increases in locomotor activity in open-fields indicative of
increased exploratory behavior and reduced general-anxiety
[74,75]. OT pre-treated subjects also travelled significantly more
distance in the emergence test which is to be expected given more
of the OT pre-treated subjects emerged from the confines of the
hidebox. However, given that an increase in locomotor activity
was also observed in the social interaction test, an effect of OT pre-
treatment on general locomotor activity cannot be ruled out.
The reductions in generalized anxiety-like behaviour observed
in this study are in line with a variety of studies demonstrating
anxiolytic properties of OT and OT receptor agonists [7,9,11,21].
However, perhaps of most interest, the present findings confirm
that OT can cause sustained reduction in general anxiety-like
behavior that remains well beyond the period during which the
administered OT is present. Several studies have found an
anxiolytic effect of OT only after chronic administration [24,25]
and in light of the present study’s findings it is plausible that the
anxiolytic effect of OT is due as much to lasting behavioral and
neuroadaptations as it is to the direct effects of administered OT,
which are presumably present for only a short time.
This longer-term reduction in anxiety caused by the short term
treatment with OT is consistent with previous reports of altered
physiological functioning (such as decreased blood pressure and
Figure 5. Alcohol and water consumption under continuous access. Mean (6 SEM) 4.44% EtOH beer and water consumption (in mls) for
each of the 25 days of continuous access to beer and water is illustrated. Continuous access began 30 days after the cessation of 10 consecutive days
of once per day treatments with either 1 mg/kg OT or equivalent VEH. Subjects were housed individually and had 24 h access to both beer and water
over the entire 25 days. N=8 per condition. * indicates sig. difference in total beer consumption between OT and VEH over the final seven days of
continuous access, p,0.05.
doi:10.1371/journal.pone.0027237.g005
Figure 6. Alcohol and water consumption following the OT
‘‘booster’’ shot. Mean (+SEM) consumption (mls) of 4.44% EtOH beer
and water over the 2.5 h following injection of a ‘‘booster’’ of either
1 mg/kg OT or equivalent VEH saline. The ‘‘booster’’ shot was
administered after the final measurement of intakes on the final
day of continuous access to beer and water. N=8 per condition.
** Significantly different to VEH, p,0.01.
doi:10.1371/journal.pone.0027237.g006
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duration of the treatment [10,26–29,71,76]. Interestingly, all of
those physiological changes are associated with a relaxed condition
[77–82]. This suggests OT may be having both a psychological
and physiological impact that is conducive to a lasting state of
reduced anxiety.
Increased sociability
More than two weeks after the cessation of pre-treatment the
subjects given OT showed a subtle but significant increase in social
behavior indicated by a greater frequency of active social contacts
and an increased duration spent in close proximity in the social
interaction test compared to VEH treated subjects. Consistent
with the assertion that OT plays an important role in the
formation and regulation of social bonds [83,84], these findings
support previous research that indicated exogenous OT causes a
reduction in social anxiety and lessens the impact of social isolation
by perhaps mimicking social interaction itself [12–15]. Further-
more, the present study extends our understanding of the effects of
exogenous OT on social behavior by providing initial evidence
that peripherally administered OT can cause longer term adaptive
behavioral changes that are conducive to reduced social anxiety
and a subsequent increase in initiations of positive social contact.
Alcohol consumption
During the 9 day alcohol induction period there were no
significant differences between OT and VEH pre-treated rats in
consumption of varying concentrations of beer. Importantly, the
lack of a significant difference in the consumption of the ‘‘near-
beer’’ base solution establishes that the later diminution in the
consumption of alcoholic beer as a result of OT pre-treatment is
unlikely to be due to basic alterations in appetite or taste aversion
as the ‘‘near-beer’’ differs from the higher concentration beer only
in EtOH content [58]. Furthermore, the lack of a significant
difference in weight between the groups throughout the alcohol
induction and continuous access stage of testing provides further
evidence that there was no difference in caloric intake between the
two conditions.
During the 25 days of continuous access to beer and water in
the home cage, which started 30 days after the cessation of drug
administration, a significant difference emerged over the access
period with OT pre-treated rats consuming significantly less
alcohol over the final week of continuous access. In line with this,
the alcohol consumption of VEH rats increased significantly over
the course of the experiment, whereas there was no significant
increase for OT rats. This provides preliminary evidence that
short-term pre-treatment with OT can inhibit the development of
alcohol consumption for at least 55 days after the cessation of the
pre-treatment regime. This is particularly exciting given the short
action of currently available treatments for alcohol abuse leads to a
very high rate of relapse resulting in a great need for treatment
options with improved long term efficacy, such as that demon-
strated by OT in this study [54,85,86].
Interestingly, as we predicted, the emergence of a stronger,
more convincing, difference in alcohol intake between VEH and
OT rats from day 19 to 25 coincides with the time-course for
development of tolerance to alcohol in standard strain and non-
alcohol preferring rats (sometimes taking up to 24 days or longer)
[61,62]. Previous studies have demonstrated OT and OT
fragments are able to reduce or eliminate tolerance to a number
of the behavioural and physiological effects of ethanol
[50,51,53,87,88]. This suggests one possibility is that the emerging
consummatory differences between VEH and OT rats in the
present study may be due to absence of tolerance in the OT-
treated subjects. Studies from the human literature also provide
anecdotal support for this theory with several studies reporting
lower tolerance to and consumption of alcohol amongst
breastfeeding mothers, in whom the central OT system is up-
regulated compared to non-lactating mothers [47–49]. Alterna-
tively, the emerging difference in ethanol consumption observed in
this study may be due to inhibition of addiction related
neuroadaptations causes by ethanol in regions such as the Nucleus
Accumbens. This is plausible given that it can take several weeks
for ethanol induced neuroadaptaions in brain regions involved in
addiction to occur [63] and OT has been shown to inhibit drug
induced activation of these regions [43]. Future studies should
explore the possibility that OT induced differences in ethanol
consumption are due to inhibition of the development of tolerance
and/or changes in the actions of ethanol in brain regions involved
in addiction.
Of importance, this study established that OT can cause long-
term reductions in alcohol consumption using a continuous access
paradigm. Demonstrating such effects under continuous access is
particularly challenging due to the constant availability of alcohol.
However, it is also arguably the most valid model given the
widespread current availability of alcohol in human society.
Figure 7. RT-PCR and ELISA. Results from the RT-PCR and ELISA conducted on the 10 rats (5 OT, 5 VEH) randomly selected 21 days after the
cessation of 10 consecutive days of once per day treatments with either 1 mg/kg OT or equivalent VEH saline. A. Fold change (6SE) in OT and OTR
mRNA expression in the OT pre-treated subjects compared to VEH. B. Mean (+SEM) blood plasma concentration of OT (pg/ml) in the OT and VEH pre-
treated subjects. *Significant fold change, p,0.05. + Trend towards significant difference compared to VEH, p=0.057.
doi:10.1371/journal.pone.0027237.g007
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there was no other source of stimulation for the rat. Such an
environment is known to be stressful, and given the direct
relationship between stress and alcohol consumption (for a review
of the negative impact of isolation on stress levels and alcohol
consumption in rats see [89]) this provided further ecological
validity to the environment in which alcohol was provided. For
example, it has been shown that socially isolated rats sometimes
consume a significantly greater quantity of ethanol than group
housed rats [90]. It is therefore possible that OT pre-treatment is
augmenting alcohol intake by preventing stress induced increases
in alcohol intake arising from the isolation housing. The fact that
OT effects were found under a paradigm so conducive to alcohol
consumption and so long after treatment is quite remarkable.
OT ‘‘booster’’ shot
In addition to the long-term suppression of alcohol consumption
seen after chronic OT administration, the ‘‘booster’’ shot of OT at
the end of the 25 day continuous access period (when consumption
patterns were established) significantly inhibited consumption of
alcohol for the 2.5 h following treatment. Furthermore, the
‘‘booster’’ treatment had no effect on the consumption of water
over the 2.5 h period, which suggests it might be an effect that is
selective to alcohol containing fluids. This provides evidence that
acute OT could be an effective and selective treatment aimed at
immediate reductions in alcohol consumption as well as an
effective option for more long-term term reductions in consump-
tion. However, the present study does not determine whether the
pre-treatment is required for the more immediate effects of the
‘‘booster’’ shot to occur. The current study therefore provides
impetus for more comprehensive future preclinical studies of OT
as a possible therapeutic for alcohol use disorders. Future studies
might utilize ‘‘near-beer’’ as a control solution (as described
previously in [58]) to determine with greater precision how specific
the consummatory suppression resulting from the ‘‘booster shot’’ is
to alcohol.
Enduring upregulation of the endogenous OT system
As expected, there was evidence of long-term enhanced
functioning of the central OT system in response to peripheral
OT treatment. OTR mRNA was significantly, albeit moderately,
upregulated and there was evidence of increased plasma levels of
OT. This is not surprising given the essential role OTRs play in
inducing and maintaining long-term neuroadaptations of the OT
system [30]. For example, increased OT levels (both central and
peripheral) and increased OTR binding, mRNA and density has
been associated with the up-regulation of the OT system that
occurs during gestation, parturition and lactation [30,91–94]. It is
plausible that upregulation of OTR mRNA is at least partly
responsible for the behavioral findings in this study given the
association between increased OTR mRNA and reduced anxiety
[95], and increased OT levels and OTR binding and reduced
alcohol consumption [96,97].
There was a strong trend towards increased OT plasma
concentration in OT pre-treated rats in this study and given
blood collection took place 21 days after treatment, it is possible
the effect was simply wearing off and would have been significant
closer to treatment. Follow up analysis of the plasma from another
study in which rats underwent a similar pre-treatment with OT or
VEH found a highly significant increase in OT plasma levels in the
OT pre-treated animals two weeks after the cessation of the pre-
treatment period (Carson, Bowen & McGregor, unpublished
findings). Furthermore, the plasma levels observed in that
experiment were similar to those observed here, providing further
support for the strong trend observed in the present study. This
provides further evidence that chronic OT administration causes a
lasting up-regulation of activity in the endogenous oxytocinergic
system and is in line with a wealth of previous studies which
demonstrate that this system is capable of undergoing morpho-
logical changes which create a positive feedback loop whereby
increased OT levels stimulate further OT release (for a review see
[30]).
Conclusion
This study has provided initial evidence that OT might have
utility as a unique pharmacotherapy with both treatment and
prophylactic utility. A brief administration of OT during early
adolescence reduced generalized and social anxiety related
behaviors in late adolescence and inhibited the development of
excessive alcohol consumption in adulthood. These behavioral
changes were associated with long-term up-regulation of the
endogenous OT system. Finally, a ‘‘booster’’ dose of OT caused
an immediate and marked reduction in alcohol consumption.
These results suggest OT, or synthetic OT receptor agonists, could
have the potential to be a beneficial and enduring treatment
option for generalized and social anxiety disorders as well as
alcohol use disorders. Current pharmacological treatment options
for these disorders are plagued by lack of efficacy and intolerable
side effects. The enduring nature of the behavioral and
morphological changes seen in this study suggests that exogenous
OT may have the capacity to do more than temporarily alleviate
pathological symptoms.
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